Regulatory News:
NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that pursuant to the liquidity contract entrusted to Invest Securities by NOXXON Pharma N.V., on December 31, 2018, the following assets appeared on the liquidity account:
- Number of shares: 30,716
- Cash balance of the liquidity account: € 19,090
As a reminder, on June 30, 2018, the following assets appeared in the liquidity account:
- Number of shares: 27,424
- Cash balance of the liquidity account: € 9,116
About NOXXON
NOXXON’s oncology-focused pipeline acts on the tumor microenvironment
(TME) and the cancer immunity cycle by breaking the tumor protection
barrier, blocking tumor repair and exposing hidden tumor cells. Through
neutralizing chemokines in the tumor microenvironment, NOXXON’s approach
works in combination with other forms of treatment to weaken tumor
defenses against the immune system and enable greater therapeutic impact.
Building
on extensive clinical experience and safety data, the lead program
NOX-A12 has delivered top-line data from a Keytruda®
combination trial in metastatic colorectal and pancreatic cancer
patients in 2018 and further studies are being planned in these
indications. The company initiated preparations for an additional trial
with NOX-A12 in brain cancer in combination with radiotherapy, for which
an orphan drug status has been granted in the US and EU. The company’s
second asset, NOX-E36 is a Phase 2 TME asset targeting the innate immune
system. NOXXON plans to test NOX-E36 in patients with solid tumors both
as a monotherapy and in combination. Further information can be found
at: www.noxxon.com
Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.
https://www.linkedin.com/company/noxxon-pharma-ag
https://twitter.com/noxxon_pharma
Disclaimer
Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190114005062/en/